Genscript Biotech R&D / Revenue
The R&D to Revenue Ratio of Genscript Biotech (1548.HK) as of Nov 6, 2026 is 7.42 %. In the previous year, R&D to Revenue Ratio was 9.05 % — a change of -17.95% (lower).
Get this data via API
Financial Data API
R&D / Revenue
7.42 %
YoY
-17.95%
Last updated:
The Genscript Biotech R&D / Revenue history
3 Years
10 Years
25 Years
Max
| YEAR | R&D / Revenue | YoY |
|---|---|---|
| 7.42 % | -17.95% | |
| 9.05 % | -3.77% | |
| 9.40 % | -84.92% | |
| 62.35 % | -11.10% | |
| 70.13 % | +4.06% | |
| 67.39 % | -0.97% | |
| 68.05 % | +112.23% | |
| 32.07 % | +171.10% | |
| 11.83 % | +43.35% | |
| 8.25 % | +0.64% | |
| 8.20 % | +2.68% | |
| 7.98 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Genscript Biotech Stock analysis
Frequently Asked Questions about Genscript Biotech stock
R&D to Revenue Ratio of Genscript Biotech is 7.42 % in 2025.
R&D to Revenue Ratio of Genscript Biotech changed from 9.05 % to 7.42 %, representing a -17.95% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Genscript Biotech since 2006 – with annual values, charts, and detailed analysis.
The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.
A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Genscript Biotech with sector peers and the industry average to assess whether it is attractive.
To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Margins — Genscript Biotech
All Key Metrics — Genscript Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth